Please assess the completion status of the following clinical trial:

Trial Title: ABT-888 and Temozolomide for Liver Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological confirmation of HCC or noninvasive criteria following AASLD guidelines~* Measurable or evaluable disease based on RECIST criteria~* Progressive disease on sorafenib or intolerance to sorafenib~* ECOG performance status 0-2~* Child Pugh Class A or B~* Adequate hepatic, bone marrow, and renal function~Exclusion Criteria:~* Prior ABT-888 or other PARP inhibitor treatment~* Anticipation of need for major surgery during the study~* Any of the following within 6 months before enrollment: myocardial infarction, severe/unstable angina, congestive heart failure, or severe pulmonary disease~* Women who are pregnant or lactating~* Women and men of child-bearing potential who are not using a reliable form of contraception~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 and temozolomide~* Concurrent malignancy (i.e. malignancy other than hepatocellular cancer) unless 1) the subject has been curatively treated and disease free for at least 2 years or 2) the cancer was non-melanoma skin cancer or early cervical cancer.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (excluding active hepatitis B or C) or psychiatric illness/ social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide and ABT-888 in HCC patients (Type: EXPERIMENTAL): Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).